A Randomised, Parallel-group, Open-label, Multicentre, 3-month Phase IV, Efficacy and Tolerability Study of Budesonide/Formoterol (Symbicort Turbuhaler 160/4.5 microg/Inhalation, 2 Inhalations Twice Daily) Added to Tiotropium (SpirivaTM 18 microg/Inhalation, 1 Inhalation Once Daily) Compared With Tiotropium (SpirivaTM18 microg/Inhalation, 1 Inhalation Once Daily) Alone in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients

Trial Profile

A Randomised, Parallel-group, Open-label, Multicentre, 3-month Phase IV, Efficacy and Tolerability Study of Budesonide/Formoterol (Symbicort Turbuhaler 160/4.5 microg/Inhalation, 2 Inhalations Twice Daily) Added to Tiotropium (SpirivaTM 18 microg/Inhalation, 1 Inhalation Once Daily) Compared With Tiotropium (SpirivaTM18 microg/Inhalation, 1 Inhalation Once Daily) Alone in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2015

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms SECURE 1
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Sep 2015 Results published in the Respirology.
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Mar 2013 Planned number of patients changed from 560 to 570 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top